Answers are grounded in this paper and cite their sources.
Our study confirms that SBRT of 35-36.25 Gy in five fractions with the CyberKnife System produces excellent control with low toxicity in patients with low-intermediate-risk prostate cancer. We found no dose-related differences in biochemical control and overall survival. Further confirmation of these results is awaited through the prospective phase of this study, which is still ongoing.
No takes yet. Share an insight, caveat, or question.
Borzillo et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: